ES3062289T3 - Factor xiia inhibitors - Google Patents
Factor xiia inhibitorsInfo
- Publication number
- ES3062289T3 ES3062289T3 ES19721369T ES19721369T ES3062289T3 ES 3062289 T3 ES3062289 T3 ES 3062289T3 ES 19721369 T ES19721369 T ES 19721369T ES 19721369 T ES19721369 T ES 19721369T ES 3062289 T3 ES3062289 T3 ES 3062289T3
- Authority
- ES
- Spain
- Prior art keywords
- factor xiia
- xiia inhibitors
- inhibitors
- factor
- xiia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1807014.4A GB201807014D0 (en) | 2018-04-30 | 2018-04-30 | Factor xlla inhibitors |
| PCT/GB2019/051180 WO2019211585A1 (en) | 2018-04-30 | 2019-04-29 | FACTOR XIIa INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3062289T3 true ES3062289T3 (en) | 2026-04-09 |
Family
ID=62495146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19721369T Active ES3062289T3 (en) | 2018-04-30 | 2019-04-29 | Factor xiia inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210087172A1 (en) |
| EP (1) | EP3788039B1 (en) |
| JP (1) | JP2021523887A (en) |
| KR (1) | KR20210005629A (en) |
| CN (1) | CN112204023A (en) |
| AU (1) | AU2019264253B2 (en) |
| CA (1) | CA3097811A1 (en) |
| ES (1) | ES3062289T3 (en) |
| GB (1) | GB201807014D0 (en) |
| WO (1) | WO2019211585A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| CN112867706B (en) | 2018-05-29 | 2024-11-15 | 奥默罗斯公司 | MASP-2 inhibitors and methods of use |
| KR20210067005A (en) * | 2019-11-28 | 2021-06-08 | 제이투에이치바이오텍 (주) | Prodrug compounds of edaravone and their medical use for treating or alleviating neurodegenerative or motor neuron diseases |
| EP4069676A1 (en) * | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| JP7699389B2 (en) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | MASP-2 inhibitors and methods of use |
| IL293550A (en) * | 2019-12-04 | 2022-08-01 | Omeros Corp | Masp-2 inhibitor compounds, compositions comprising same and uses thereof |
| BR112022010881A2 (en) | 2019-12-04 | 2022-08-23 | Omeros Corp | COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD TO TREAT A DISEASE OR DISORDER ASSOCIATED WITH SERINE PROTEASE-2 ASSOCIATED WITH MANAN-BINDING LECTIN |
| JP2023552747A (en) | 2020-12-01 | 2023-12-19 | カルビスタ・ファーマシューティカルズ・リミテッド | enzyme inhibitor |
| JP2023554346A (en) | 2020-12-18 | 2023-12-27 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for modulating factor XII |
| TW202302565A (en) | 2021-02-19 | 2023-01-16 | 英商卡爾維斯塔製藥有限公司 | Enzyme inhibitors |
| TW202412765A (en) | 2022-08-18 | 2024-04-01 | 英商卡爾維斯塔製藥有限公司 | Enzyme inhibitors |
| TW202425999A (en) | 2022-10-19 | 2024-07-01 | 英商卡爾維斯塔製藥有限公司 | Enzyme inhibitors |
| WO2024218503A1 (en) | 2023-04-20 | 2024-10-24 | Kalvista Pharmaceuticals Limited | Solid forms of an enzyme inhibitor and salts thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| AU709088B2 (en) * | 1995-10-24 | 1999-08-19 | Merck & Co., Inc. | Thrombin inhibitors |
| CA2200163A1 (en) * | 1996-03-22 | 1997-09-22 | Michael Robert Wiley | Antithrombotic diamides |
| IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Serine protease inhibiting antithrombotic agents and pharmaceutical compositions comprising them |
| DE69921358T2 (en) | 1998-12-23 | 2006-03-09 | Bristol-Myers Squibb Pharma Co. | NITROGENIC HETEROBICYCLES AS FACTOR XA HEMMER |
| DE19962924A1 (en) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituted oxazolidinones and their use |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
| EP2655399B1 (en) * | 2010-12-21 | 2017-09-27 | The Medicines Company (Leipzig) GmbH | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa |
| WO2018093695A1 (en) * | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
-
2018
- 2018-04-30 GB GBGB1807014.4A patent/GB201807014D0/en not_active Ceased
-
2019
- 2019-04-29 JP JP2020560768A patent/JP2021523887A/en active Pending
- 2019-04-29 EP EP19721369.7A patent/EP3788039B1/en active Active
- 2019-04-29 CN CN201980036679.0A patent/CN112204023A/en active Pending
- 2019-04-29 CA CA3097811A patent/CA3097811A1/en active Pending
- 2019-04-29 WO PCT/GB2019/051180 patent/WO2019211585A1/en not_active Ceased
- 2019-04-29 US US17/050,350 patent/US20210087172A1/en not_active Abandoned
- 2019-04-29 KR KR1020207032768A patent/KR20210005629A/en not_active Withdrawn
- 2019-04-29 AU AU2019264253A patent/AU2019264253B2/en active Active
- 2019-04-29 ES ES19721369T patent/ES3062289T3/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3788039A1 (en) | 2021-03-10 |
| CA3097811A1 (en) | 2019-11-07 |
| EP3788039B1 (en) | 2026-02-11 |
| AU2019264253B2 (en) | 2023-02-23 |
| CN112204023A (en) | 2021-01-08 |
| KR20210005629A (en) | 2021-01-14 |
| JP2021523887A (en) | 2021-09-09 |
| US20210087172A1 (en) | 2021-03-25 |
| EP3788039C0 (en) | 2026-02-11 |
| AU2019264253A1 (en) | 2020-11-19 |
| GB201807014D0 (en) | 2018-06-13 |
| WO2019211585A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106520VA (en) | Kif18a inhibitors | |
| ES3062289T3 (en) | Factor xiia inhibitors | |
| IL277006A (en) | Cd73 inhibitors | |
| ZA201905811B (en) | Novel inhibitors | |
| IL304348A (en) | Cd73 inhibitors | |
| ZA202107835B (en) | Prc2 inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| SG11202010347XA (en) | Stat3 inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL283112A (en) | Lox inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| EP3833374C0 (en) | PROTEASOMIC INHIBITORS | |
| GB201809295D0 (en) | Lox inhibitors | |
| GB2578396B (en) | Amidodiamine corrosion inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| HK40044877A (en) | Factor xiia inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors |